Penumbra Inc


SKU: PEN Category:


Penumbra Inc: Initiation Of Coverage – A Tale Of Cautious Innovation!


This is our first report on Penumbra, a global healthcare major. The company reported its fourth quarter and annual earnings on its conference call. The company made a revenue of USD 284.7 million in Q4, marking a year-over-year increase of 28.7%, while their annual revenues for 2023 reached USD 1,058.5 million, a 25% increase compared to 2022. This strong performance resulted from the company’s legacy in thrombectomy technology and their innovative approaches to treating clot patients. The company’s CEO, Adam Elsesser, stated that a key aspect was their innovative Lightning Flash and Lightning Bolt 7 technologies that managed to achieve a new trajectory in their VTE and arterial thrombectomy operations.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!